Latest Reimbursement News

Emyria has begun treating the first Medibank-funded PTSD patients at its Perth clinic, marking a pioneering step in private insurance coverage for psychedelic-assisted therapy in Australia. This milestone fuels rapid clinic expansion and supports the company’s national rollout strategy.

Polynovo Limited reported a robust 23.3% increase in total revenue for FY25, driven by strong commercial sales growth across the US and international markets. The company is advancing its FDA PMA submission and expanding its global footprint amid strategic product development.

Beacon Minerals has exercised its option to acquire the historic Wealth of Nations gold tenements, confirming high-grade mineralisation through an 11-hole drill program and setting the stage for a maiden resource estimate in 2026.

Nex Metals Explorations has partnered with the Wangkatja Tjungula Aboriginal Corporation to reprocess historic gold tailings at Kookynie, sharing profits and embedding cultural stewardship in rehabilitation efforts.

Sierra Nevada Gold (ASX – SNX) has qualified to bid for exploration licenses in Saudi Arabia’s Arabian Shield, leveraging its regional expertise to tap into a promising new frontier aligned with the Kingdom’s Vision 2030.

Medical Developments International reports a strong FY25 with significant margin gains and strategic progress, setting the stage for accelerated Penthrox expansion in FY26.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase in H1 2025, driven by strong sales of its precision medicine products and strategic acquisitions. The company is advancing multiple late-stage clinical trials and expanding its global manufacturing footprint.

Artrya Limited has secured FDA 510(k) clearance for its Salix Coronary Plaque module, enabling near real-time detection of high-risk coronary artery plaque and opening a lucrative U.S. market opportunity with a $950 reimbursement per scan.

Artrya Limited reported a 17.2% increase in net loss to $16.4 million for FY25, while achieving FDA clearance and launching its AI-driven Salix platform in the U.S. market. The company also secured key commercial partnerships in Australia and raised $20 million in equity funding.

Amplitude Energy has delivered record production and earnings in FY25, driven by operational improvements and a strategic joint venture for the East Coast Supply Project.

Amplitude Energy Limited reported a 22% revenue increase to A$268.1 million for FY25, narrowing its net loss significantly while progressing its East Coast Supply Project with a new joint venture partner.

Cleo Diagnostics has launched a health economic study in partnership with EntityRisk and Norstella to support the U.S. market entry of its Ovarian Cancer Pre-Surgical Test, aiming to refine reimbursement strategies and accelerate commercialisation.